论文部分内容阅读
目的:分析比较更昔洛韦胶囊与注射用更昔洛韦于骨髓移植术后人巨细胞病毒(CMV)感染的有效性与安全性。方法:在骨髓移植术后CMV感染患者中随机抽取18例,9例给予更昔洛韦胶囊优先治疗,9例给予注射用更昔洛韦优先治疗,直至CMV显阴性,继续维持治疗6周,保持CMV阴性。结果:更昔洛韦胶囊和注射用更昔洛韦治疗总有效率100%,转阴时间差异无显著性。均有不同程度的白细胞和血细胞的减少和转氨酶的升高,疑与用药有关。结论:更昔洛韦胶囊与注射用更昔洛韦于骨髓移植术后CMV感染的有效性与安全性差异无显著性。
Objective: To compare the efficacy and safety of ganciclovir capsules and ganciclovir for the treatment of human cytomegalovirus (CMV) infection after bone marrow transplantation. Methods: 18 cases were randomly selected from patients with CMV infection after bone marrow transplantation, 9 cases were treated with ganciclovir capsules preferentially, 9 cases were treated with ganciclovir for injection preferentially, until CMV was negative, the treatment was continued for 6 weeks, Keep CMV negative. Results: The total effective rate of ganciclovir capsules and ganciclovir for injection was 100%. No significant difference was found between the time of negative conversion. Have varying degrees of white blood cells and blood cells decreased and elevated transaminases, suspected drug-related. Conclusion: There is no significant difference between the efficacy and safety of ganciclovir capsules and ganciclovir for CMV infection after bone marrow transplantation.